Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer

Cancer Biotherapy & Radiopharmaceuticals Jun 2017, Vol. 32, No. 5: 176-183.


from Mary Ann Liebert, Inc. publishers via xlomafota13 on Inoreader http://ift.tt/2rG2FRg
via IFTTT